BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target ...

整体上，通过氨基酸残基间的相互作用，多肽形成了特定的三维结构以识别并结合 OX2 受体。 作用机理及研究进展 作用机理：(Ala11,D-Leu15)-Orexin B 是一种高效且选择性的 OX2 受体激动剂，对 OX2 受体的选择性比对 OX1 受体高 400 倍 。当它与 OX2 受体结合后，会诱导 ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming urge to crawl back into bed. But some people wake up fresh and energized after ...

RBC Capital initiated coverage of Alkermes (ALKS) with a Sector Perform rating and $40 price target The company’s next-generation orexin has a ...

Analysts have recently evaluated Harmony Biosciences Hldgs and provided 12-month price targets. The average target is $58.0, ...

Dr Leah Kaylor, a psychologist and sleep expert says: “Occasionally, more sleep may be required after emotionally intense ...

The two major types of narcolepsy are: Narcolepsy type 1. People with type 1 narcolepsy have low levels of orexin (hypocretin), a brain chemical that regulates wakefulness. Damage to the brain ...

2025年3月12日周三，Alkermes Plc（NASDAQ: ALKS）在2025年Leerink全球医疗大会上发表演讲，重点介绍了其Orexin管线和强劲商业产品的战略重点。公司在竞争压力下强调了其神经科学领域的重点和增长战略，同时阐述了机遇与挑战。